Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Vanessa Schneider, Lu Zhang, Markus Rojewski, Lars Bullinger, MD PhD, Susanne Hofmann, MD, Marlies Goetz, Konstanze Doehner, MD, Hartmut Doehner, Prof., Christian Buske, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 5783.

https://doi.org/10.1182/blood.V124.21.5783.5783

Published: 2014

Journal Articles

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Vanessa Schneider, Lars Bullinger, MD, PhD, Lu Zhang, Markus Rojewski, Markus Wiesneth, Susanne Hofmann, Marlies Goetz, Hubert Schrezenmeier, MD, Ulla Botzenhardt, Thomas F.E. Barth, Konstanze Doehner, MD, Hartmut Doehner, MD, Jochen Greiner, MD

Blood (2013) 122 (21): 2624.

https://doi.org/10.1182/blood.V122.21.2624.2624

Published: 2013

Journal Articles

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

Lu Zhang, Susanne Hofmann, Lars Bullinger, Marlies Goetz, Markus Wiesneth, Markus Rojewski, Hartmut Dohner, MD, Jochen Greiner, MD, Vanessa Schneider

Blood (2011) 118 (21): 4997.

https://doi.org/10.1182/blood.V118.21.4997.4997

Published: 2011

Journal Articles

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Jochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, Isabel Funk, Marta Heyduk, Markus Rojewski, Jinfei Chen, Marlies Goetz, Martin Bommer, Gerd Ritter, Phillipe Guillaume, Anna Dmoszynska, Hartmut Döhner, Michael Schmitt

Blood (2008) 112 (11): 2911.

https://doi.org/10.1182/blood.V112.11.2911.2911

Published: 2008

Journal Articles

Peptide Vaccine Preparation and Validation with a Bio-Assay

Anita Schmitt, Clemens Bechter, Junxia Yao, Marlies Goetz, Birgit Maccari, Peter Schauwecker, Markus Wiesneth, Michael Schmitt

Blood (2008) 112 (11): 5444.

https://doi.org/10.1182/blood.V112.11.5444.5444

Published: 2008

Journal Articles

The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.

Jochen Greiner, Lars Bullinger, Krzysztof Giannopoulos, Anita Schmitt, Marlies Goetz, Lena Kienle, Hartmut Döhner, Michael Schmitt

Blood (2008) 112 (11): 1524.

https://doi.org/10.1182/blood.V112.11.1524.1524

Published: 2008

Journal Articles

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Jochen Greiner, MD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Jinfei Chen, MD, Marlies Goetz, Markus Rojewski, MD, Gerd Ritter, PhD, Sascha Gnjatic, PhD, Philippe Guillaume, PhD, Mark Ringhoffer, MD, Martin Bommer, MD, Richard F. Schlenk, MD, Peter Liebisch, MD, Donald Bunjes, MD, Hiroshi Shiku, PhD, Hartmut Dohner, MD, Michael Schmitt, MD

Blood (2007) 110 (11): 1806.

https://doi.org/10.1182/blood.V110.11.1806.1806

Published: 2007

Journal Articles

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Fei Fei, MD, Yingzhe Yu, Anita Schmitt, MD, Jinfei Chen, PhD, MD, Baoan Chen, PhD, MD, Markus Rojewski, MD, Mark Ringhoffer, MD, Stefanie von Harsdorf, MD, Jochen Greiner, PhD, MD, Marlies Goetz, Philippe Guillaume, PhD, Hartmut Dohner, PhD, MD, Donald Bunjes, PhD, MD, Michael Schmitt, PhD, MD

Blood (2007) 110 (11): 2368.

https://doi.org/10.1182/blood.V110.11.2368.2368

Published: 2007

NARROW

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Peptide Vaccine Preparation and Validation with a Bio-Assay

The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only